Michael Weiss, TG Therapeutics CEO
May 31, 2022 10:00 AM EDTUpdated 05:00 PM
R&D
FDA+

TG Ther­a­peu­tics gets 3-month punt from FDA for stand­alone BLA in af­ter­math of Ukoniq + ad­comm with­draw­al

Paul Schloesser

Associate Editor

Just over a month af­ter B-cell ma­lig­nan­cy and au­toim­mune-fo­cused biotech TG Ther­a­peu­tics with­drew its ap­pli­ca­tion for blood can­cer com­bo U2 one week be­fore an ad­comm …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times